Single User
£3750
PDF
42 pages

Amyotrophic Lateral Sclerosis Forecast in 9 Major Markets 2016-2026


Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease or motor neuron disease, is a is a rapidly progressive, fatal neurological disease in which upper and lower motor neurons degrade and eventually die. As motor function decreases, muscles weaken and waste; eventually the brain is no longer able to control autonomic functions such as breathing and heart rate.

This report provides the current prevalent population for ALS across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of ALS have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for ALS include:

  • Loss of speech
  • Depression
  • Dysphagia
  • Tongue twitch
  • Dementia (e.g. Frontotemporal lobe dementia)
  • Mild cognitive impairment
  • Breathing difficulties (e.g. dyspnoea)
  • Respiratory failure

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in the global ALS market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of ALS and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on ALS’s prevalent population.
  • Identify sub-populations within ALS which require treatment.
  • Gain an understanding of the specific markets that have the largest number of ALS patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Amyotrophic Lateral Sclerosis
  • Features of ALS Patients
    • Origin of ALS
    • Sporadic ALS Patient Features and Comorbidities
    • ALS Patients with Bulbar Onset
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
  List of Tables
  • Prevalence of ALS, total (000s)
  • Prevalence of ALS, males (000s)
  • Prevalence of ALS, females (000s)
  • Origin of ALS presenting in patients, total (000s)
  • Clinical phenotype in ALS patients, total (000s)
  • Region of onset in GLOBAL phenotype ALS patients, total (000s)
  • Sporadic ALS patients with SOD1 mutation, total (000s)
  • Prevalence of mild cognitive impairment in sporadic ALS patients, total (000s)
  • Prevalence of dementia in sporadic ALS patients, total (000s)
  • Prevalence of dementia by type in sporadic ALS, total (000s)
  • Prevalence of loss of speech in bulbar onset ALS, total (000s)
  • Prevalence of dysphagia in bulbar onset ALS, total (000s)
  • Prevalence of tongue twitch in bulbar onset ALS, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of ALS by 5-yr age cohort, males (000s)
  • USA Prevalence of ALS by 5-yr age cohort, females (000s)
  • France Prevalence of ALS by 5-yr age cohort, males (000s)
  • France Prevalence of ALS by 5-yr age cohort, females (000s)
  • Germany Prevalence of ALS by 5-yr age cohort, males (000s)
  • Germany Prevalence of ALS by 5-yr age cohort, females (000s)
  • Italy Prevalence of ALS by 5-yr age cohort, males (000s)
  • Italy Prevalence of ALS by 5-yr age cohort, females (000s)
  • Spain Prevalence of ALS by 5-yr age cohort, males (000s)
  • Spain Prevalence of ALS by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of ALS by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of ALS by 5-yr age cohort, females (000s)
  • Brazil Prevalence of ALS by 5-yr age cohort, males (000s)
  • Brazil Prevalence of ALS by 5-yr age cohort, females (000s)
  • Japan Prevalence of ALS by 5-yr age cohort, males (000s)
  • Japan Prevalence of ALS by 5-yr age cohort, females (000s)
  • India Prevalence of ALS by 5-yr age cohort, males (000s)
  • India Prevalence of ALS by 5-yr age cohort, females (000s)
Brazil, France, Germany, India, Italy, Japan, Spain, United Kingdom, United States of America